Bayer (BAYN) PT Set at €100.00 by Barclays

Barclays set a €100.00 ($116.28) price objective on Bayer (FRA:BAYN) in a research report report published on Tuesday. The brokerage currently has a buy rating on the healthcare company’s stock.

BAYN has been the topic of a number of other reports. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of Bayer and gave the company a buy rating in a research report on Monday, August 13th. Commerzbank set a €111.00 ($129.07) price target on shares of Bayer and gave the company a buy rating in a research report on Monday, August 13th. Goldman Sachs Group set a €116.00 ($134.88) price target on shares of Bayer and gave the company a buy rating in a research report on Monday, August 13th. Baader Bank set a €140.00 ($162.79) price target on shares of Bayer and gave the company a buy rating in a research report on Wednesday, August 1st. Finally, Cfra set a €100.00 ($116.28) price target on shares of Bayer and gave the company a buy rating in a research report on Tuesday, August 14th. Seven equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of €94.61 ($110.02).

Shares of BAYN opened at €62.59 ($72.78) on Tuesday. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: What does the Dow Jones Industrial Average (DJIA) measure?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply